Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ch program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines, the interpretation of the CAPACITY clinical data, including certain exploratory analyses conducted by the Company with respect to such data and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company currently intends to submit in support of its NDA and MAA filings. Further analyses of the CAPACITY results will be conducted in the future and additional observations may be made whi
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 Synthetic Biologics, Inc. ... biologic and drug candidates targeting specific pathogens that ... Biotechnologies UK Limited (Fujifilm), announced today confirmation of ... manufacturing of SYN-004, Synthetic Biologics, proprietary oral beta-lactamase ... ( C. difficile ) infections. ...
(Date:8/27/2014)... China, Aug. 28, 2014 China Nepstar ... or the "Company"), a leading retail drugstore chain ... operated stores, today announced its unaudited financial results ... Financial HighlightsFor the quarter ended June 30, 2014: ... million (US$110.7 million) compared to RMB638.8 million in the ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... Co-development Terms & Agreements in ... https://www.reportbuyer.com/product/2276221/Co-development-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The Co-development Terms ... report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science ...
Breaking Medicine Technology:Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7
... 2007 - OSI,Pharmaceuticals, Inc. (Nasdaq: OSIP) announced ... of Clinical Oncology show that,adding Tarceva(R) (erlotinib) ... as first-line,therapy to patients with advanced pancreatic ... National Cancer Institute of Canada (NCIC),formed the ...
... STRASBOURG, France and VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ ... pharmaceutical and medical device company, announced that,the ... examining the,Vascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will ... in Europe. The,two-year study examined the safety ...
Cached Medicine Technology:OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7
(Date:8/28/2014)... Clarity PSO , an operating division of ... Patient Safety Organization (PSO) for another three-year period under ... Quality (AHRQ). Clarity PSO will continue to provide valuable ... true intentions of the Patient Safety and Quality Improvement ... eager to continue our journey as a PSO and ...
(Date:8/28/2014)... San Franisco, CA (PRWEB) August 28, 2014 ... emerging marijuana business sector recently launched a “Video” ... relevant news and general information on various cannabis ... section, individuals can find an assortment of news ... marijuana-related issues and announcements. A portion of the ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider of ... to help clients and online readers send out summer ... Han Ashley developed variations of Roasted Veggie Pizza ... The PreDiabetes Centers Roasted Veggie Pizza recipe is made ... features a cheese substitute–ideal for people who are lactose ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Vitals, a recognized ... Dr. Sabrina Fabi of Cosmetic Laser Dermatology one of their ... of thousands of patients to share their doctor experiences and ... manner, face time, and follow-ups. The Vitals Top 10 Doctor ... Dr. Fabi was ranked one of the highest by patients. ...
(Date:8/28/2014)... 28, 2014 It is not uncommon for ... unsuccessful dieting attempts. Many face ridicule and judgment and find ... thoughts and feelings, wondering why they keep gaining weight and ... solace in comfort foods, eating more and gaining more, leaving ... , Diet Doc has helped thousands safely, successfully and ...
Breaking Medicine News(10 mins):Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3Health News:Dr. Sabrina Fabi of Cosmetic Laser Dermatology Recognized as Vitals Top 10 Doctor 2Health News:Diet Doc’s Medical Weight Loss Programs Announce New Help for Patients Who Want to Overcome Depression Caused by Excess Weight 2Health News:Diet Doc’s Medical Weight Loss Programs Announce New Help for Patients Who Want to Overcome Depression Caused by Excess Weight 3
... Offers Hope to Millions of Couples Seeking a Better Sex,Life, ... relieved by the,preliminary results of a new study that demonstrates ... lives. The exercises take,just 5 minutes a day but the ... who followed the simple PelvicToner exercise,programme reported an improved sex ...
... to farms, particularly to barns and farm milk, while ... to a group of German researchers, who will present ... Conference in Toronto on Wednesday, May 21., In a ... 59 non-farming mothers, the researchers believe they have proved ...
... their Prescription History, WALNUT CREEK, Calif., May ... ) announced today a new collaboration with,Google Health ... between,patients and providers. Working with Google, Longs will ... customers with the ability to import their,prescription information ...
... 18, 2008 TAP Pharmaceutical Products Inc. today reported ... new drug TAK-390MR, the first proton pump inhibitor (PPI) ... patients with erosive esophagitis (EE) and in maintenance of ... Disease Week (DDW) annual meeting in San Diego. , ...
... over T-cell counts for monitoring HIV treatment , ... can help identify those whose treatment will succeed or ... from pharmacy records, works at least as well as ... the immune system, according to research published in PLoS ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
Cached Medicine News:Health News:Is Female Sexual Dysfunction a Myth? 2Health News:Farm moms may help children beat allergies 2Health News:Longs Drugs Partners With Google on the Launch of Google Health 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 2Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 3Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 4Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 5Health News:Mapping of prostate cancer genes opens the door to new treatments 2
Designed for simple operation, the Model 515B pulse oximeter is ideal for use in any clinical setting; from emergency hospital transport to continuous monitoring in Anesthesia, Intensive Care and Gen...
... The Models 512 and 513 handheld ... This advanced technology is able to ... resolutions and speeds of 100 times ... in improved pulse oximeter performance during ...
... Whether it's for an emergency situation, bedside ... Handheld Capnograph / Pulse Oximeter delivers accurate ... This portable, handheld monitor now contains Nellcors ... compatible with OxiMax sensors. The NPB-75 monitor ...
The new Nellcor N-45 Handheld Pulse Oximeter is compatible with our complete line of OxiMax Pulse Oximetry Sensors, so clinicians have the convenience of Nellcors most advanced sensor technology in a...
Medicine Products: